A promising new approach to advanced prostate cancer is being developed. Dr. Saul Priceman and colleagues are working on engineered gamma-delta T cells designed to recognise multiple cancer targets, helping overcome tumour resistance. www.pcf.org/c/congratula...
A new class of multiple myeloma treatment has arrived. The FDA has approved Zenbexus in combination therapy for previously treated patients, the first approved CELMoD protein degrader for multiple myeloma. www.oncologynewscentral.com/drugs/info/f...
Improving prostate cancer care through education. The Prostate Cancer Foundation & Bayer have launched a new programme bringing VA healthcare professionals together to share advances in precision oncology. www.pcf.org/pcf-and-baye...
An unexpected avenue for cancer research: scientists report that sildenafil, the active ingredient in Viagra, reduced cancer spread in laboratory and animal models by disrupting how cancer cells use cholesterol. www.oncology-central.com/viagra-shows...
More cancer patients may become eligible for clinical trials. New FDA guidance encourages broader eligibility criteria, potentially opening studies to patients previously excluded because of health status & results. www.oncologynewscentral.com/oncology/fda...
Could CAR-T therapy finally become more effective against solid tumours? USC researchers have developed a technique using focused ultrasound to give tumours a target that engineered immune cells can recognise and attack. viterbischool.usc.edu/news/2026/08...